soul trial semaglutide ADA 2025: Oral Demonstrates Cardiovascular Benefits in New data from the SOUL

Not all primary care doctors are trained in modern obesity medicine, and some may be hesitant to prescribe these medications due to the administrative burden of insurance paperwork

Pet Gala is built for that visible, everyday confirmation of care

doi: 10.3390/nu13082831 30

We conducted a comprehensive literature search across databases, including PubMed and Web of Science, compiling data from clinical trials, case reports, and basic research studies published up to 2025, with a focus on the efficacy, safety, and mechanism of action of drugs such as liraglutide, semaglutide, and tirzepatide in patients with MC4R deficiency